XML 20 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Revenues [Abstract]      
Total revenue $ 333,785 $ 280,324 $ 321,793
Operating expenses:      
Research and development 72,405 81,866 90,388
Sales and marketing 81,718 83,334 96,027
General and administrative 123,784 117,868 100,397
Restructuring costs 1,783 2,320 0
Litigation expense (96,300) 96,300 0
Total operating expenses 293,020 483,687 399,024
Income (loss) from operations 40,765 (203,363) (77,231)
Other income (expense):      
Interest income, net 11,765 11,867 3,762
Change in estimated fair value of common stock warrant liability 0 10 107
Other income (expense), net 329 1,343 (2,872)
Total other income 12,094 13,220 997
Income (loss) before income taxes 52,859 (190,143) (76,234)
Income tax expense (310) (141) (379)
Net income (loss) $ 52,549 $ (190,284) $ (76,613)
Net income (loss) per share (Note 3):      
Basic (in dollars per share) $ 1.00 $ (3.54) $ (1.44)
Diluted (in dollars per share) $ 0.93 $ (3.54) $ (1.44)
Weighted-average shares used to compute net income (loss) per share:      
Basic (in shares) 52,773,247 53,764,705 53,321,625
Diluted (in shares) 56,620,590 53,764,705 53,321,625
Testing services revenue      
Revenues [Abstract]      
Total revenue $ 249,381 $ 209,685 $ 263,748
Operating expenses:      
Cost of testing services, product, patient and digital solutions 55,611 57,642 72,286
Product revenue      
Revenues [Abstract]      
Total revenue 40,783 33,517 29,251
Operating expenses:      
Cost of testing services, product, patient and digital solutions 23,381 18,379 17,639
Patient and digital solutions      
Revenues [Abstract]      
Total revenue 43,621 37,122 28,794
Operating expenses:      
Cost of testing services, product, patient and digital solutions $ 30,638 $ 25,978 $ 22,287